.png)
WoundClot (Core Scientific Creations)
Cellulose hemostatic trauma gauze for point-of-injury bleeding control (WoundClot)
Latest event found: 8 Aug 2026 · 2 months ago
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
WoundClot appears focused on expanding adoption of its bioresorbable cellulose hemostatic gauze across prehospital, military, emergency, surgical, and international distributor channels. Recent activity emphasizes clinical evidence, thought leadership, and market education rather than a clearly documented new product, financing, acquisition, or major organizational expansion.
Efficiency Ratio
The company appears resource-efficient for its recorded 11–50-person scale, maintaining regulatory credibility and international distribution reach with a relatively lean operating footprint, although independently verified revenue and delivery-volume data are limited.
Evidence Signals
Core Scientific Creations leadership promoted a white paper describing WoundClot use across point-of-injury care, emergency departments, operating rooms, postoperative care, vascular access, and austere environments.
A LinkedIn post promoted WoundClot's technology and cited a 97.18% hemostatic success rate from the WCS-1 study.
Life-Assist featured WoundClot in its field medical solutions portfolio, positioning it alongside other bleeding-control products for emergency and transport applications.
- About
- Israeli hemostatics company — legal entity Core Scientific Creations Ltd. (Petah Tikva; founded 2012; founder/CEO Yuval Yaskil; US arm Core Scientific North America, Inc.), known worldwide by its product brand WoundClot. WoundClot hemostatic gauze is the world's only Non-Oxidized, Non-Regenerated Cellulosic Structure (NONRCS) hemostatic: engineered cellulose that is inherently hemostatic with no impregnated active agent — on blood contact it converts from dry gauze into a tenacious, adhesive 3D gel matrix that absorbs up to ~2,500% of its weight, controls capillary, venous and arterial bleeding non-compressionally, and remains effective up to 24 hours, including in coagulopathic or anticoagulated patients. The surgical line is a CE Class III implantable, bioabsorbable device with the fastest resorption profile available (~7-14 days). FDA-cleared (510(k) K160679, 2016) and CE-marked; distributed in 32 countries; adopted by Israeli police forces after the 2016 attacks and deployed during October 2023. Explicitly built for pre-hospital civilian and military hemorrhaging trauma — a pure-play point-of-injury hemorrhage-control ('stop the bleed' / TCCC) fit, used by military medics, EMS and surgeons (cardiovascular/orthopedic/ENT).
- Tags
- #hemostatic #bleedingcontrol #gauze #trauma #tccc #stopthebleed #cellulose #fda #ce #military #dualuse